Bristol-Myers Squibb’s first quarter results reflected a blend of strong execution in its newer growth portfolio and ongoing ...

Bristol-Myers Squibb (NYSE:BMY) recently announced dividend declarations for common and preferred stock, potentially adding ...

BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big ...

Retail investor chatter around Bristol Myers Squibb intensified on Monday following the release of new clinical data, which ...

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's third consecutive day of losses.

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the 17 stocks that Jim Cramer commented on. During the episode, Cramer ...

In accordance with the agreement, Philochem will get $350 million up front and could get up to $1 billion in milestone ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...